US Stocks Movement | BlossomHill Therapeutics (BLSM.US) Listed on US Stock Market, Shares Slightly Declined After Opening

According to Jinse Finance APP, on Friday, BlossomHill Therapeutics (BLSM.US) debuted on the US stock market. As of press time, the stock was down over 1%, trading at $15.8. BlossomHill Therapeutics is headquartered in San Diego, California, and was founded in 2020. The company focuses on developing small molecule cancer drugs by identifying structural weaknesses in existing therapies and designing new compounds to overcome these shortcomings. Its core candidate drug, BH-30643, targeting EGFR-mutant non-small cell lung cancer (NSCLC), is currently undergoing global Phase I/II clinical trials. The company plans to hold an end-of-Phase I meeting with the US Food and Drug Administration (FDA) in the fourth quarter of 2026 to discuss the recommended Phase II dosing regimen and potential accelerated approval pathways for certain patients.